Eu­ro­pean Com­mis­sion lays ground­work to un­wind Il­lu­mi­na's $7B+ Grail merg­er

The Eu­ro­pean Com­mis­sion has rec­om­mend­ed steps that — though not yet fi­nal — would re­quire Il­lu­mi­na to “swift­ly” un­wind its con­tro­ver­sial $7.1 bil­lion Grail buy­out.

The Com­mis­sion de­liv­ered a “state­ment of ob­jec­tions” on Mon­day, de­tail­ing the process Il­lu­mi­na would need to take in di­vest­ing Grail, its blood test­ing spin­out launched in 2016. Il­lu­mi­na re-ac­quired Grail back in Au­gust, de­spite crit­i­cism from both the FTC and EU.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER